Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)
The inability to generate mesenchymal stromal cells (MSCs) of consistent potency likely is responsible for inconsistent clinical outcomes of patients with aGvHD receiving MSC products. We developed a novel MSC manufacturing protocol characterized by high in vitro potency and near-identity of individ...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
29 January 2018
|
| In: |
Bone marrow transplantation
Year: 2018, Volume: 53, Issue: 7, Pages: 852-862 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-018-0102-z |
| Online Access: | Verlag, Volltext: https://doi.org/10.1038/s41409-018-0102-z Verlag: https://www.nature.com/articles/s41409-018-0102-z 
|
| Author Notes: | Peter Bader, Zyrafete Kuçi, Shahrzad Bakhtiar, Oliver Basu, Gesine Bug, Michael Dennis, Johann Greil, Aniko Barta, Krisztián M. Kállay, Peter Lang, Giovanna Lucchini, Raj Pol, Ansgar Schulz, Karl-Walter Sykora, Irene von Luettichau, Grit Herter-Sprie, Mohammad Ashab Uddin, Phil Jenkin, Abdulrahman Alsultan, Jochen Buechner, Jerry Stein, Agnes Kelemen, Andrea Jarisch, Jan Soerensen, Emilia Salzmann-Manrique, Martin Hutter, Richard Schäfer, Erhard Seifried, Thomas Klingebiel, Halvard Bonig, Selim Kuçi |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1691312053 | ||
| 003 | DE-627 | ||
| 005 | 20230428055044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200302s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-018-0102-z |2 doi | |
| 035 | |a (DE-627)1691312053 | ||
| 035 | |a (DE-599)KXP1691312053 | ||
| 035 | |a (OCoLC)1341308578 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bader, Peter |d 1962- |e VerfasserIn |0 (DE-588)1069884367 |0 (DE-627)822886286 |0 (DE-576)429571380 |4 aut | |
| 245 | 1 | 0 | |a Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM) |c Peter Bader, Zyrafete Kuçi, Shahrzad Bakhtiar, Oliver Basu, Gesine Bug, Michael Dennis, Johann Greil, Aniko Barta, Krisztián M. Kállay, Peter Lang, Giovanna Lucchini, Raj Pol, Ansgar Schulz, Karl-Walter Sykora, Irene von Luettichau, Grit Herter-Sprie, Mohammad Ashab Uddin, Phil Jenkin, Abdulrahman Alsultan, Jochen Buechner, Jerry Stein, Agnes Kelemen, Andrea Jarisch, Jan Soerensen, Emilia Salzmann-Manrique, Martin Hutter, Richard Schäfer, Erhard Seifried, Thomas Klingebiel, Halvard Bonig, Selim Kuçi |
| 264 | 1 | |c 29 January 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.03.2020 | ||
| 520 | |a The inability to generate mesenchymal stromal cells (MSCs) of consistent potency likely is responsible for inconsistent clinical outcomes of patients with aGvHD receiving MSC products. We developed a novel MSC manufacturing protocol characterized by high in vitro potency and near-identity of individual doses, referred to as “MSC-Frankfurt am Main (MSC-FFM)”. Herein, we report outcomes of the 69 patients who have received MSC-FFM. These were 51 children and 18 adults with refractory aGvHD grade II (4%), III (36%) or IV (59%). Patients were refractory either to frontline therapy (steroids) (29%) or to steroids and 1-5 additional lines of immunosuppressants (71%) were given infusions in four weekly intervals. The day 28 overall response rate was 83%; at the last follow-up, 61% and 25% of patients were in complete or partial remission. The median follow-up was 8.1 months. Six-month estimate for cumulative incidence of non-relapse mortality was 27% (range, 16-38); leukemia relapse mortality was 2% (range, 0-5). This was associated with a superior six-month overall survival (OS) probability rate of 71% (range, 61-83), compared to the outcome of patients not treated with MSC-FFM. This novel product was effective in children and adults, suggesting that MSC-FFM represents a promising therapy for steroid refractory aGvHD. | ||
| 700 | 1 | |a Greil, Johann |e VerfasserIn |0 (DE-588)1078331979 |0 (DE-627)838332455 |0 (DE-576)450711498 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 53(2018), 7, Seite 852-862 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM) |
| 773 | 1 | 8 | |g volume:53 |g year:2018 |g number:7 |g pages:852-862 |g extent:11 |a Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM) |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-018-0102-z |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-018-0102-z |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200302 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1078331979 |a Greil, Johann |m 1078331979:Greil, Johann |d 910000 |d 910500 |e 910000PG1078331979 |e 910500PG1078331979 |k 0/910000/ |k 1/910000/910500/ |p 7 | ||
| 999 | |a KXP-PPN1691312053 |e 360151687X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"recId":"1691312053","note":["Gesehen am 02.03.2020"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Bader, Peter","given":"Peter","family":"Bader"},{"given":"Johann","family":"Greil","role":"aut","display":"Greil, Johann","roleDisplay":"VerfasserIn"}],"title":[{"title":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)","title_sort":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group","publisherPlace":"London ; Basingstoke ; London"}],"id":{"issn":["1476-5365"],"zdb":["2004030-1"],"eki":["320433366"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 17.01.25"],"disp":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)Bone marrow transplantation","language":["eng"],"recId":"320433366","pubHistory":["Nachgewiesen 19.1997 -"],"part":{"year":"2018","issue":"7","pages":"852-862","volume":"53","text":"53(2018), 7, Seite 852-862","extent":"11"},"title":[{"title_sort":"Bone marrow transplantation","title":"Bone marrow transplantation"}]}],"physDesc":[{"extent":"11 S."}],"name":{"displayForm":["Peter Bader, Zyrafete Kuçi, Shahrzad Bakhtiar, Oliver Basu, Gesine Bug, Michael Dennis, Johann Greil, Aniko Barta, Krisztián M. Kállay, Peter Lang, Giovanna Lucchini, Raj Pol, Ansgar Schulz, Karl-Walter Sykora, Irene von Luettichau, Grit Herter-Sprie, Mohammad Ashab Uddin, Phil Jenkin, Abdulrahman Alsultan, Jochen Buechner, Jerry Stein, Agnes Kelemen, Andrea Jarisch, Jan Soerensen, Emilia Salzmann-Manrique, Martin Hutter, Richard Schäfer, Erhard Seifried, Thomas Klingebiel, Halvard Bonig, Selim Kuçi"]},"id":{"eki":["1691312053"],"doi":["10.1038/s41409-018-0102-z"]},"origin":[{"dateIssuedDisp":"29 January 2018","dateIssuedKey":"2018"}]} | ||
| SRT | |a BADERPETEREFFECTIVET2920 | ||